Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, North American Phase III TARGET 1 trial in 600 patients showed that 41% of patients treated with 550 mg oral Xifaxan thrice daily for 14 days achieved adequate relief of IBS symptoms for at least 2 weeks during the first 4 weeks of follow-up, the primary endpoint, vs. 31% for placebo (p=0.0125). Additionally, 40% of Xifaxan-treated patients achieved adequate relief of IBS-related bloating vs. 29% for placebo (p=0.0045). Data were presented at the Digestive Disease Week meeting in New Orleans. Salix previously reported that Xifaxan met the primary endpoint in the trial (see BioCentury, Sept. 21, 2009). ...